BioScrip Inc (NASDAQ:BIOS) reached a new 52-week low on Thursday . The company traded as low as $1.68 and last traded at $1.73, with a volume of 33625 shares traded. The stock had previously closed at $1.72.

A number of research analysts recently commented on the company. BidaskClub downgraded BioScrip from a “sell” rating to a “strong sell” rating in a research note on Wednesday, March 6th. Canaccord Genuity dropped their price target on BioScrip from $5.00 to $3.50 and set a “buy” rating for the company in a research note on Monday, March 18th. Stephens downgraded BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 price target for the company. in a research note on Monday, March 18th. Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. Finally, TheStreet downgraded BioScrip from a “c-” rating to a “d” rating in a research note on Wednesday, April 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $4.70.

The company has a market cap of $219.15 million, a P/E ratio of -3.49 and a beta of 0.69.

BioScrip (NASDAQ:BIOS) last released its earnings results on Friday, March 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.11). The business had revenue of $183.57 million during the quarter, compared to analysts’ expectations of $188.39 million. During the same quarter in the previous year, the company posted ($0.03) EPS. The firm’s revenue was up .5% on a year-over-year basis. On average, equities research analysts anticipate that BioScrip Inc will post -0.25 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in BIOS. Maven Securities LTD bought a new position in BioScrip in the fourth quarter valued at about $45,000. FNY Investment Advisers LLC grew its position in BioScrip by 840.9% in the first quarter. FNY Investment Advisers LLC now owns 25,000 shares of the company’s stock valued at $50,000 after acquiring an additional 22,343 shares during the last quarter. Caxton Associates LP bought a new position in BioScrip in the fourth quarter valued at about $52,000. Virtu Financial LLC grew its position in BioScrip by 60.6% in the fourth quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock valued at $65,000 after acquiring an additional 6,868 shares during the last quarter. Finally, Menta Capital LLC bought a new position in BioScrip in the fourth quarter valued at about $124,000. Hedge funds and other institutional investors own 82.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://theolympiareport.com/2019/04/20/bioscrip-bios-hits-new-1-year-low-at-1-68.html.

About BioScrip (NASDAQ:BIOS)

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.